Neural correlates of attention-executive dysfunction in lewy body dementia and Alzheimer's disease. [PDF]
, 2015 Attentional and executive dysfunction contribute to cognitive impairment in both Lewy body dementia and Alzheimer's disease. Using functional MRI, we examined the neural correlates of three components of attention (alerting, orienting, and executive ...
Alan J. Thomas +101 more
core +1 more source
Journal of the Neurological Sciences, 2019 Diffuse Lewy body disease, also called dementia with Lewy bodies (DLB), is defined as progressive dementia and pathological Lewy bodies distributed in the central and autonomic nervous systems. The clinical features are dementia, cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD).
Yu Wei Lin, Daniel Truong
openaire +4 more sources
A new visual rating scale for Ioflupane imaging in Lewy body disease
NeuroImage: Clinical, 2018 Background: Dopaminergic loss on 123I-Ioflupane brain imaging is a recognised biomarker for dementia with Lewy bodies. It is usually assessed using a visual rating scale developed for Parkinson's disease, which may not be optimal for dementia with Lewy ...
Jim J. Lloyd +7 more
doaj +1 more source
What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review [PDF]
, 2017 Distinguishing dementia subtypes can be difficult due to similarities in clinical presentation. There is increasing interest in discrete gait characteristics as markers to aid diagnostic algorithms in dementia.
Galna, Brook +5 more
core +2 more sources
Neuropathology, 1998 Diffuse Lewy body disease (DLBD) has been studied from various viewpoints and, although clinical diagnostic criteria for DLBD have been proposed, diagnosis remains difficult. DLBD has been reported to be the second most common form of dementia in the aged, following Alzheimer‐type dementia. It has, however, been clinically under‐diagnosed.
openaire +8 more sources
α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies
npj Parkinson's Disease, 2023 There is increasing interest in studying retinal biomarkers for various neurodegenerative diseases. Specific protein aggregates associated with neurodegenerative diseases are present in the retina and could be visualised in a non-invasive way. This study
Frederique J. Hart de Ruyter +10 more
doaj +1 more source
Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. [PDF]
, 2014 BackgroundIn dementia with Lewy bodies (DLB) abnormal interactions between α-synuclein (α-syn) and beta amyloid (Aβ) result in selective degeneration of neurons in the neocortex, limbic system and striatum.
Cartier, Anna +9 more
core +3 more sources
Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample [PDF]
, 2017 © 2017 The Authors Introduction Rapid eye movement sleep behavior disorder (RBD) is strongly associated with synucleinopathies. In 2012, we reported an increased risk of mild cognitive impairment (MCI) and Parkinson disease (PD) in cognitively normal ...
Boeve, Bradley F +11 more
core +2 more sources
A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease
Acta Neuropathologica Communications, 2019 Lewy body diseases are neurodegenerative disorders characterized by Lewy bodies in the brain. Lewy body dementia (LBD) refers to two forms of Lewy body disease: Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB).
Benjamin R. Smith +6 more
doaj +1 more source
Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. [PDF]
, 2015 OBJECTIVE: The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia.
Cambridge, Victoria +9 more
core +2 more sources